Mr Iain Ross (Non-Executive Chairman) joined the Company on 1 May 2017. Iain currently serves as Non-Executive Chairman of AIM quoted e-Therapeutics plc and Biomer Technology Ltd alongside his Non-Executive Directorships at London listed Premier Veterinary Group plc, ASX quoted Anatara LifeSciences Ltd and Novogen Ltd, and as a Director of Aldershot Town Football Club.
Iain’s previous executive positions include Executive Chairman at Silence Therapeutics plc (2005-2010), Chief Executive Officer at Allergy Therapeutics (2001-2002), Chief Executive Officer at Quadrant Healthcare plc (1995-2000) and Main Board Director of Celltech Group plc and CEO of Celltech Biologics (1991-1995). He has also been a Non-Executive Director at Benitec Biopharma (2010-2016), Phadia AB (2004-2007) and Eden BioDesign (2003-2007). Prior to this he worked at several multinational companies including Sandoz AG, Fisons plc and Hoffman La Roche. Mr Ross is a qualified Chartered Director (UK IoD) and Vice Chairman of Royal Holloway, London University.
Dr Neil Murray (CEO) co-founded the Company in 2010 and has over 25 years' experience in the pharmaceutical industry with experience of drug development, business growth and general management. He has held a variety of senior operational, commercial and R&D positions including as Global Director for Sales and Marketing with Solutia's Pharmaceutical Services business. Prior to joining Solutia he was Director of Chemical Development at Vernalis (formerly Vanguard Medica) with additional responsibility for management of the company's research portfolio. He was also European Business Development Director for SigmaAldrich before which he was External Projects Director at GlaxoWellcome with responsibility for the company's external development science. He has extensive experience of drug discovery and development and commercialisation in large and small companies across a wide range of therapeutic areas.
Mr Norman Molyneux (Non-Executive Director) was previously the CFO of the Company before becoming a Non-Executive Director in September 2014. Norman is a qualified Chartered Management Accountant and has 15 years’ experience in arranging early stage business angel and venture capital funding. Following training in accountancy with GKN, he joined PriceWaterhouseCoopers, working on many consultancy assignments with both SME and multinational companies. Following this, he returned to industry with Director roles in the paper manufacturing and food manufacturing sectors in the UK. In 2000, Norman founded Acceleris Capital Limited, an FCA regulated fund management and corporate finance firm specialising in EIS-led investment transactions. Norman holds numerous Directorships fulfilling both executive and non-executive positions.
Dr Bernhard Kirschbaum (Non-Executive Director) joined the Board in January 2016. Bernhard has over 25 years' experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company's R&D portfolio, with over 70 programs, doubling the number of phase II assets in this period. Dr Kirschbaum is currently Chairman of Protagen Diagnostics and a board member of BioMedX and OMEICOS Therapeutics.
David Lawrence (Non-Executive Director) joined the Board in May 2016. David has over 25 years' experience in the biotech and pharmaceutical industries with a strong track record in strategy, business development and commercial management, including working with a number of investors, biotech start-ups and SMEs. He is currently a Non-Executive Director at Synpromics Ltd, a synthetic biology company that he co-founded. In 2014-2015 he was CEO of Sentintext Therapeutics, a biotech focussed on the development of vaccines for enterviruses. He was also a director of QSpine Limited, which designs, manufactures and distributes surgical spine medical devices. David has been Chairman of Ambicare Health Limited, CEO of Tayside Flow Technologies Ltd and formerly worked at Chiron Vaccines (now part of Novartis), Acambis plc (now part of Sanofi), and GlaxoSmithKline.
Dr Neil Murray (CEO), as above
Dr Richard Armer (CSO) joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard's expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.
Nicholas Adams (CBO) joined as the Company's first Chief Business Officer at the end of 2015. Nick has over 25 years' experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.
Dr Matilda Bingham (Head of Research & Operations) has 14 years’ experience in drug discovery and joined the company in 2012. Matilda’s scientific background is in medicinal chemistry having worked at Organon, Schering-Plough and Merck (MSD) before joining the management team at Redx Pharma. Matilda played a key role in setting up the Redx Oncology subsidiary including laboratory design, recruitment, development of health and safety policies and the creation of the current project portfolio. In 2015 she was promoted from Head of Chemistry to Executive Director and currently manages the Oncology and Immunology subsidiaries.
Dr Karl Hård (Head of Investor Relations and Corporate Communications) has spent almost 20 years at AstraZeneca, the last nine of which included senior roles within Investor Relations, latterly as Vice President. Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.
Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and holds a PhD in Chemistry from Utrecht University, and an MSc in Biochemistry from Helsinki University, Finland.
Andrew Booth (Interim Finance Director) holds a degree in Law from Liverpool University, and is a qualified member of the Institute of Chartered Accountants in England & Wales. His areas of expertise include listed company work and International Financial Reporting Standards. Andrew started his career with PKF (now BDO LLP), before moving to work in industry, taking on a number of senior financial roles in AIM and Euronext listed companies (including that of Company Secretary). He joined Redx Pharma as Group Financial Controller in July 2015 and became Interim Finance Director in September 2016.